Trial Profile
The effect of multiple-dose eslicarbazepine acetate (ESL) on the pharmacokinetic parameters of a single dose of rosuvastatin in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary) ; Rosuvastatin (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Pharmacodynamics
- 13 Feb 2018 New trial record